Are Cannabis’ Cannabinoid Receptors Implicated in Agitation Control in Dementia?

PostedMarch 12, 2026

UpdatedMarch 12, 2026

ByMy Patient Advice

Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

Growing research is exploring whether the body’s cannabinoid receptors may influence agitation in dementia. According to NHS guidance on medical cannabis, while cannabis-based medicinal products are licensed for a few conditions, their use in dementia remains unproven due to limited clinical evidence.

Understanding Cannabinoid Receptors

Cannabinoid receptors (CB1 and CB2) are part of the body’s endocannabinoid system, which helps regulate mood, memory, and behaviour. Evidence from a 2024 systematic review suggests that stimulating these receptors may reduce agitation and aggression in some people living with dementia, though results vary widely.
The BMJ review (2022) notes that cannabinoids might modulate neural inflammation and neurotransmitter activity linked to behavioural symptoms, but most trials remain small or short-term.

What The Guidelines Say

According to NICE NG144 and NICE NG97, cannabis-based medicinal products are not currently recommended for managing behavioural symptoms of dementia. The 2023 NICE surveillance review found that while emerging studies are promising, evidence quality remains insufficient for clinical recommendation.

The MHRA and GMC both require clinicians to prescribe only where products meet regulatory and ethical standards, under specialist supervision. The CQC also expects providers to demonstrate safe, compliant use of any cannabis-based medicinal treatment.

Current Research Insights

Clinical data are still developing. A Swiss feasibility study (2024) found that cannabis oil containing THC and CBD was well-tolerated in people with dementia, with modest reductions in agitation. The PubMed 2023 study observed improvements in behavioural symptoms through CB1 and CB2 receptor modulation but stressed the need for large scale trials.
UK-based initiatives such as the STAND trial are further investigating cannabis’ role in dementia, while the Alzheimer’s Society advises that current evidence does not support routine clinical use.

Clinical Bottom Line

Cannabinoid receptors are biologically linked to behavioural regulation but remain under-researched in dementia.

Small studies suggest potential benefits for agitation, yet findings are inconsistent.

NICE and NHS do not currently recommend cannabis for agitation in dementia.

Prescribing remains limited to specialist settings under strict MHRA and GMC frameworks.

Larger, placebo-controlled studies are required before clinical adoption.

Educational Context: AlleviMed

AlleviMed provides public education about medical cannabis eligibility and regulation in the UK. It helps patients understand how cannabis-based medicinal products are prescribed under Home Office and MHRA standards, without promoting or facilitating treatment.

Takeaway

Cannabinoid receptors appear to play a role in brain processes related to agitation, but medical cannabis remains an unproven therapy for dementia. According to NICE and NHS, current evidence is not strong enough to recommend routine clinical use. Further trials, such as those supported by Alzheimer’s Research UK, will help determine whether these pathways can safely and effectively improve quality of life for people living with dementia.

Julia Sutton, MSc

Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy.

Dr. Clarissa Morton, PharmD

Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy.